RAM
AUPH icon

Riggs Asset Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Riggs Asset Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-200
Closed -$1.55K – 426
2023
Q3 		$1.55K Buy
+200
New +$1.96K ﹤0.01% 358

Other funds holding AUPH

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Riggs Asset Management's AUPH Position: Q4 2023 in Review

Riggs Asset Management sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2023, closing a stake of 200 shares — an estimated $1.55K sold.

Riggs Asset Management first reported a position in AUPH in Q3 2023 and held it in 1 quarter. The position peaked at $1.55K in Q3 2023. 191 funds tracked by Wall St. Rank hold AUPH as of Q4 2023.

  • Riggs Asset Management reported no remaining Aurinia Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Riggs Asset Management sold 200 Aurinia Pharmaceuticals shares in Q4 2023, an estimated $1.55K.
  • Riggs Asset Management first reported a position in Aurinia Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Riggs Asset Management's Aurinia Pharmaceuticals position peaked at $1.55K in Q3 2023.
  • 191 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2023.

Based on Riggs Asset Management's 13F filing for Q4 2023, filed 1 Feb 2024.